BACKGROUND: @entity319 ( @entity319 ) tyrosine kinase inhibitors (TKIs) have widely been used in advanced @entity5 . However, these drugs may also lead to serious adverse events. The present meta-analysis aimed to determine the overall incidence and risk of @entity204 due to @entity319 -TKIs with more detailed subgroup analysis. MATERIALS AND METHODS: PubMed, Web of Science, and Cochrane databases were searched for randomized controlled trials (RCTs) that compared @entity319 -TKIs with non- @entity319 -TKIs in the treatment of solid @entity5 . Pooled incidence, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random-effects or fixed-effects models based on the heterogeneity of included trials. RESULTS: A total of 14,139 @entity1 from 41 RCTs were enrolled. The pooled incidence of @entity204 due to @entity319 -TKIs was 1.9% (95% CI: 1.6%-2.3%) with an OR of 1.85 (95% CI: 1.33-2.58; P<0.01) when compared with control groups. On subgroup analysis, significantly increased risk of @entity204 was found in @entity1 with @entity1149 (OR: 2.37; 95% CI: 1.19-4.73; P=0.01) and @entity14 (OR: 2.84; 95% CI: 1.02-7.96; P=0.05). Among different @entity319 -TKIs, @entity2857 and @entity2240 had significant risk of @entity204 when compared with control arms, respectively. @entity319 -TKIs in combination with other antineoplastic agents, but not @entity319 -TKI monotherapy, significantly increased the risk of treatment-related @entity204 . No heterogeneity was noted across all the prespecified subgroups regarding ORs. CONCLUSION: The present work pointed out a significantly increased risk of @entity204 due to @entity319 -TKIs. Close monitoring should be emphasized in @entity1 receiving these drugs.

Risk of treatment-related XXXX with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.

@entity1 :: ('9606', 'Species') :: ['participants', 'patients'] @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['nonsmall-cell lung cancer'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity319 :: ('3791', 'Gene') :: ['VEGFR', 'Vascular endothelial growth factor receptor'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']
@entity204 :: (MESH:D003643,Disease) :: ['deaths']
